Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Seres Therapeutics (MCRB) Leases (2019 - 2025)

Seres Therapeutics' Leases history spans 7 years, with the latest figure at $74.7 million for Q3 2025.

  • For Q3 2025, Leases fell 9.94% year-over-year to $74.7 million; the TTM value through Sep 2025 reached $74.7 million, down 9.94%, while the annual FY2024 figure was $80.9 million, 10.52% down from the prior year.
  • Leases for Q3 2025 was $74.7 million at Seres Therapeutics, down from $76.8 million in the prior quarter.
  • Across five years, Leases topped out at $111.0 million in Q4 2022 and bottomed at $8.4 million in Q1 2021.
  • The 5-year median for Leases is $78.9 million (2025), against an average of $66.2 million.
  • The largest annual shift saw Leases skyrocketed 509.53% in 2022 before it fell 25.65% in 2025.
  • A 5-year view of Leases shows it stood at $18.2 million in 2021, then surged by 509.53% to $111.0 million in 2022, then dropped by 18.53% to $90.4 million in 2023, then fell by 10.52% to $80.9 million in 2024, then fell by 7.71% to $74.7 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Leases are $74.7 million (Q3 2025), $76.8 million (Q2 2025), and $78.9 million (Q1 2025).